| Minute dosages of ανβ3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits | |||||||||||||
Abstract | |||||||||||||
| Fumagillin suppresses angiogenesis in cancer models and clinical trials, but it is associated with neurotoxicity at systemic doses. In this study, ανβ3-targeted fumagillin nanoparticles were used to suppress the neovasculature and inhibit Vx-2 adenocarcinoma development using minute drug doses. Tumor-bearing rabbits were treated on days 6, 9, and 12 postimplantation with ανβ3-targeted fumagillin nanoparticles (30 μg/kg), ανβ3-targeted nanoparticles without drug, nontargeted fumagillin nanoparticles (30 μg/kg) or saline. On day 16, MRI was performed with ανβ3-targeted paramagnetic nanoparticles to quantify tumor size and assess neovascularity. Tumor volume was reduced among rabbits receiving ανβ3-targeted fumagillin nanoparticles (470±120 mm3) compared with the three control groups: nontargeted fumagillin nanoparticles (1370±300 mm3, P | |||||||||||||
Publication details | |||||||||||||
| |||||||||||||